Oral and injectable Marsdenia tenacissima extract (MTE) as adjuvant therapy to chemotherapy for gastric cancer: a systematic review

Table 2 Subgroup analysis stratified by injectable and oral Marsdenia tenacissima extract

Outcome	Injectable MTE subgroup			Oral MTE subgroup			Interaction P value
Outcome	No. of studies	Estimate (95% CI)	I²	No. of studies	Estimate (95% CI)	I²	Interaction P value
Response to treatment	12	POR 2.02 (1.58–2.58)	0%	2	POR 1.94 (1.04–3.60)	0%	0.90
Performance status	7	POR 2.94 (1.99–4.34)	0%	1	POR 4.31 (1.89–9.84)	0%	0.41
Leukopenia	12	RR 0.68 (0.57–0.82)	42%	3	RR 0.57 (0.36–0.90)	44%	0.48
Thrombocytopenia	11	RR 0.67 (0.49–0.93)	33%	2	RR 0.42 (0.11–1.59)	69%	0.50
Nausea/vomiting	9	RR 0.82 (0.71–0.94)	0%	2	RR 0.47 (0.29–0.78)	0%	0.04
Hepatic injury	9	RR 0.83 (0.62–1.12)	19%	2	RR 0.61 (0.39–0.95)	0%	0.25

Note: Subgroup analysis was unavailable for anemia, diarrhea, constipation, kidney injury, peripheral neurotoxicity, and oral mucosal lesions because all trials that assessed these outcomes used injectable Marsdenia tenacissima extract
Abbreviations: MTE Marsdenia tenacissima extract; POR proportional odds ratio; RR risk ratio; CI confidence interval

ISSN: 2662-7671